Evidence Grade D — Primarily preclinical. 22 published studies, mostly animal models. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Ovagen is a synthetic tripeptide from the Khavinson bioregulator programme, proposed to target liver tissue. Peer-reviewed publications specifically on Ovagen are essentially absent from indexed scientific databases. It has no regulatory approval and no verifiable clinical or preclinical data.
Ovagen is also known by these brand and alternate names:
22 published studies: 0 human, 20 animal, 5 in-vitro, 0 reviews
Ovagen has no marketing authorisation from any major regulatory agency. Direct peer-reviewed publications specifically on this compound are essentially absent from indexed scientific databases. Vendor materials cite preclinical studies, but these could not be independently verified.
The inability to locate verifiable peer-reviewed evidence for this specific compound in standard scientific databases represents a significant evidence gap. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Ovagen may influence liver-specific gene expression. However, verifiable peer-reviewed publications on this specific compound could not be confirmed in accessible scientific databases. The proposed mechanisms are based on the broader Khavinson bioregulation framework.
This compound has the weakest evidence base in this batch. Virtually no Ovagen-specific peer-reviewed publications exist in accessible scientific databases. Most evidence is extrapolated from related Khavinson peptides rather than demonstrated for this specific compound. No clinical trials, no confirmed animal studies, no pharmacokinetic data, and no safety data exist for this specific peptide. An unresolved discrepancy between the capsule formulation ingredient and the research peptide sequence raises product identity questions. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for Ovagen sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Ovagen is a synthetic tripeptide bioregulator with the sequence Glu-Asp-Leu (EDL). Its molecular formula is C15H25N3O8 with a molecular weight of 375.37 Da (PubChem CID 444128, CHEBI 137252). Developed by Vladimir Khavinson as part of the cytomedine program, Ovagen targets liver and hepatic tissue despite the name suggesting ovarian function. A significant discrepancy exists: the capsule product (AC-3) lists ingredients as lysine, glutamic acid, and aspartic acid (suggesting KED), while research literature identifies EDL as the active sequence. No pharmacokinetic data exist. It is the weakest-evidenced compound in this batch.
Research suggests EDL crosses cell and nuclear membranes and interacts with DNA to influence liver-specific and gastrointestinal transcription patterns. Proposed uptake occurs via POT family peptide transporters (PEPT1, PEPT2). The peptide is reported to promote hepatocyte regeneration, reduce fibrotic markers, and modulate protein synthesis. EDL has been independently characterized as an HIV-1 protease inhibitor (Ki approximately 50 microM in a 1998 Western structural biology study), but this is pharmacologically unrelated to claimed hepatoprotective effects. Khavinson framework publications describe short peptide bioregulation through DNA interaction, but no Ovagen-specific mechanistic studies exist in indexed literature.
Direct peer-reviewed publications specifically on Ovagen (the branded EDL peptide) are essentially absent from indexed databases. Vendor materials cite claims of CCl4 and paracetamol-induced hepatotoxicity mitigation attributed to Khavinson et al. 2012 and Kozina et al. 2011, but these could not be verified in accessible databases. The only independently validated finding involving the EDL tripeptide is its HIV-1 protease inhibition at Ki approximately 50 microM (Louis et al. 1998, Biochemistry), which confirms sequence-specific bioactivity but is unrelated to hepatoprotection.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 5 vendor listings
View pricing data across vendors and countries for Ovagen
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Palopegteriparatide is marketed as Yorvipath (Ascendis Pharma, approved August 2024). It is the first FDA-approved PTH replacement therapy for hypoparathyroidism, a condition that previously had no approved hormone replacement and was managed only with high doses of calcium supplements and active vitamin D — an approach that does not fully normalise calcium metabolism. In the PaTHway trial, 79% of patients achieved independence from calcium and active vitamin D supplements while maintaining normal blood calcium levels, compared to 5% on placebo. This represents a fundamental shift in managing hypoparathyroidism — from supplementation to actual hormone replacement. Patients also showed improvements in kidney function markers and bone metabolism parameters.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
